LAS VEGAS, Sept. 4, 2014 (GLOBE NEWSWIRE) -- GrowBLOX Sciences, Inc., aka GB Sciences (OTCQB:GBLX) has expanded to the East Coast to make its brand of proprietary Cannabis-based medications available to patients in new markets. The new entity, GB Sciences East, LLC, will be headquartered in Manhattan and is moving quickly to obtain medical marijuana establishment licenses in New York, New Jersey, and New Hampshire.
"State medical marijuana application processes have become increasingly complex as regulatory agencies have reacted to failures in other states and now require larger amounts of documentation to ensure only the most responsible entities can participate in their medical marijuana programs," says Craig Ellins, CEO of GB Sciences.
"States are adopting more rigorous regulations and are more discerning about who can participate—which is exactly what they should be doing to protect their citizens," said Ellins. "Our State Application and Compliance Team is experienced and skilled at navigating government licensing application processes. More importantly, we are also uniquely qualified in our ability to offer a range of clinically tested medical-grade marijuana strains that are so consistent, doctors will feel confident recommending our Cannabis to their patients because they deliver predictable results. That's the really good news."
About GrowBLOX Sciences, Inc.
GrowBLOX Sciences, Inc., aka GB Sciences, Inc. (OTCQB:GBLX), is a medical marijuana research and development company that offers solutions for the commercialization of medical marijuana and is working to improve the quality of life for people suffering from a variety of poorly controlled medical conditions by creating consistent quality and potency in its Cannabis strains and cannabinoid-based therapies that target specific medical conditions.
To learn more, go to www.gbsciences.com
Forward-Looking Statements
Except for historical information contained herein, the statements in this release are forward-looking and made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are inherently unreliable and actual results may differ materially. Examples of forward-looking statements in this news release include statements regarding the payment of dividends, marketing and distribution plans, development activities and anticipated operating results. Factors which could cause actual results to differ materially from these forward-looking statements include such factors as the Company's ability to accomplish its business initiatives, significant fluctuations in marketing expenses and ability to achieve and expand significant levels of revenues, or recognize net income, from the sale of its products and services, as well as the introduction of competing products, or management's ability to attract and maintain qualified personnel necessary for the development and commercialization of its planned products, and other information that may be detailed from time to time in the Company's filings with the United States Securities and Exchange Commission. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.